FDA says Synthetix Inc., doing business as Helix Chemical Supply, sold unapproved and misbranded Semaglutide and Tirzepatide drugs online.
What happened
FDA reviewed www.helixchem.com in October 2023 and observed that the website offered Semaglutide and Tirzepatide products for sale in the United States. FDA says dose schedules and claims on the site—despite "research use only" and "not for human consumption" statements—show the products are intended as drugs for human use. FDA found no approved applications for the products and says their labeling lacks adequate directions for use, making them unapproved new drugs and misbranded drugs.
What FDA found
FDA says the company offered Semaglutide and Tirzepatide as new drugs without FDA-approved applications.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)FDA says the products are misbranded because their labeling does not give adequate directions for use.
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)FDA says website dose schedules and claims, including blood sugar, insulin, heart, liver, lung, Alzheimer's, and Mounjaro references, show the products are intended for human use as drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA says the products are prescription drugs because of their toxicity or potential for harmful effects, how they are used, or the supervision needed for use.
FD&C Act section 503(b)(1)(A), 21 U.S.C. 353(b)(1)(A)FDA says introducing or delivering misbranded drugs into interstate commerce is prohibited.
FD&C Act section 301(a), 21 U.S.C. 331(a)
What FDA wants
Respond in writing within 15 working days of receipt of the letter with the specific steps taken to address the violations, how recurrence will be prevented, and related documentation; if corrective actions are not complete, give the reason and planned completion date. Send the response to FDA's Office of Unapproved Drugs and Labeling Compliance by email.
Who should pay attention
- online sellers of research-use-only peptides
- clinics or pharmacies buying or offering GLP-1 drugs
- consumers purchasing semaglutide or tirzepatide online
This is a summary. Read the original letter on fda.gov.